Supranuclear Palsy, Progressive
"Supranuclear Palsy, Progressive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
| Descriptor ID |
D013494
|
| MeSH Number(s) |
C10.228.140.079.882 C10.228.662.700 C10.292.562.750.500 C10.574.945.500 C10.597.622.447.690 C11.590.472.500 C23.888.592.636.447.690
|
| Concept/Terms |
Supranuclear Palsy, Progressive- Supranuclear Palsy, Progressive
- Progressive Supranuclear Palsies
- Supranuclear Palsies, Progressive
- Palsy, Progressive Supranuclear
- Progressive Supranuclear Ophthalmoplegia
- Progressive Supranuclear Palsy
- Steele-Richardson-Olszewski Disease
- Steele Richardson Olszewski Disease
- Steele-Richardson-Olszewski Syndrome
- Steele Richardson Olszewski Syndrome
- Syndrome, Steele-Richardson-Olszewski
- Supranuclear Palsy, Progressive, 1
- Ophthalmoplegia, Progressive Supranuclear
- Supranuclear Ophthalmoplegia, Progressive
- Richardson's Syndrome
- Richardson Syndrome
- Syndrome, Richardson's
|
Below are MeSH descriptors whose meaning is more general than "Supranuclear Palsy, Progressive".
Below are MeSH descriptors whose meaning is more specific than "Supranuclear Palsy, Progressive".
This graph shows the total number of publications written about "Supranuclear Palsy, Progressive" by people in this website by year, and whether "Supranuclear Palsy, Progressive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2016 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Supranuclear Palsy, Progressive" by people in Profiles.
-
Utilizing speech analysis to differentiate progressive supranuclear palsy from Parkinson's disease. Parkinsonism Relat Disord. 2023 10; 115:105835.
-
Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 09; 78:56-60.
-
Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? Parkinsonism Relat Disord. 2019 12; 69:34-39.
-
Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019 09; 66:166-170.
-
Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord. 2018 03; 33(3):468-472.
-
Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017 02; 35:75-81.
-
Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model. Neuron. 2016 Oct 19; 92(2):407-418.
-
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 07; 28:41-48.
-
The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun. 2014 May 29; 2:56.
-
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.